A Study in Healthy Men to Test How BI 1569912 is Processed in the Body
1상
완료
NCT06520553
| 대상 질환 | Healthy |
|---|
| 임상 단계 | 1상 |
|---|
| 스폰서 | Boehringer Ingelheim |
|---|
| 상태 | 완료 |
|---|
| 참여자 수 | 8 명 |
|---|
| 중재(약물) | BI 1569912 (C-14), BI 1569912 (C-13) |
|---|
| 시작일 | 2024년 8월 26일 |
|---|
| 완료일 | 2024년 10월 3일 |
|---|
| 결과 공개일 | 2026년 5월 22일 |
|---|
요약
The main objectives of this trial are: * To investigate basic pharmacokinetics of BI 1569912 and total radioactivity, including mass balance, excretion pathways and metabolism following oral administration of BI 1569912 (C-14) to healthy male subjects (test treatment, T). * To investigate the absolute bioavailability of BI 1569912 as single oral solution dose, using a single, concomitant intravenous micro-tracer administration of BI 1569912 (C-13) (reference treatment, R)
Fraction Excreted in Urine as Percentage of the Administered Dose Over the Time Interval From 0 to the Last Quantifiable Time Point (fe Urine,0-tz) of [14C]-Radioactivity
Up to 14 days. · Percentage of administered dose
| 10 Milligram (mg) BI 1569912 (C-14) Oral Solution (Test Treatment) | 57.0 ± 10.9 Percentage of administered dose |
|---|
Fraction Excreted in Faeces as Percentage of the Administered Dose Over the Time Interval From 0 to the Last Quantifiable Time Point (fe Faeces,0-tz) of [14C]-Radioactivity
Up to 14 days. · Percentage of administered dose
| 10 Milligram (mg) BI 1569912 (C-14) Oral Solution (Test Treatment) | 31.1 ± 62.9 Percentage of administered dose |
|---|
Total Recovery of [14C]-Radioactivity
Up to 14 days. · Percentage of administered dose
| 10 Milligram (mg) BI 1569912 (C-14) Oral Solution (Test Treatment) | 91.2 ± 12.7 Percentage of administered dose |
|---|
BENITIONS에서 보기
ClinicalTrials.gov 원문 보기
전체 임상
이 페이지는 ClinicalTrials.gov의 공개 데이터를 정리한 것입니다. 의학적 조언이 아니며 투자 권유나 자문도 아닙니다. 반드시 전문의와 상담하세요.